Scott Gottlieb

Scott Gottlieb is an American physician and conservative health policy analyst. He is a clinical assistant professor at New York University School of Medicine, a resident fellow at the conservative American Enterprise Institute, and an internist at Tisch Hospital.^[1] Dr. Gottlieb was appointed by the Senate Majority Leader to serve as a member of the Federal Health IT Policy Committee which advises the Department of Health and Human Services. ^[2] He is a regular contributor to the editorial page of the Wall Street Journal and authors a regular feature on Forbes.com. ^[3] He also appears regularly on CNBC and Fox News. Dr. Gottlieb serves as a member of the Public Policy Committee to the Society of Hospital Medicine, is an adviser to the National Coalition for Cancer Survivorship, and is a member of the editorial board of the Food and Drug Law Institute's Policy Forum. He is a venture partner at New Enterprise Associates, one of the world's largest, oldest, and most active venture capital firms; and is an independent director at Tolero Pharmaceuticals,^[4] and Daiichi Sankyo Inc,^[5] and a member of GlaxoSmithKline's product investment board -- the company's senior-most research and development committee. He is also a partner at T.R. Winston, a Los Angeles-based merchant bank with a focus on healthcare. Dr. Gottlieb completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine of the New York University and of Wesleyan University, in Middletown, Connecticut, where he studied Economics. ^[6] Dr. Gottlieb has testified 18 times as an expert witness before committees of the United States House of Representatives and the United States Senate on issues related to FDA regulation, healthcare reform, and medical innovation.

Previous positions

Dr. Gottlieb has previously served in multiple Federal government capacities, including Deputy Commissioner for Medical and Scientific Affairs at the Food and Drug Administration, in which capacity he served from 2005 to 2007.^[7] Among other things, Dr. Gottlieb helped initiate the early development of FDA's generic drug user fee program and the Agency's release of the Physician Labeling Rule. Dr. Gottlieb also worked on development of the FDA's policies related to the tentative approval of fixed dose combination drugs for the treatment of HIV under the PEPFAR program. Dr. Gottlieb was appointed to the Senior Executive Service and granted a top secret security clearance during his appointment as FDA's Deputy Commissioner for Medical and Scientific Affairs. He also served as a member of the White House Biodefense Interagency Working Group, which was convened after the September 11, 2001 attacks to help draft a strategic plan for the development of biodefense countermeasures. While working for the FDA, Dr. Gottlieb had to recuse himself from working on planning for a possible bird flu epidemic due to his ties to pharmaceutical companies.^[8] Before becoming the FDA's Deputy Commissioner, Dr. Gottlieb served as a senior advisor to the FDA Commissioner and as the FDA's Director of Medical Policy Development. ^[9] He has also served as a senior policy advisor to the Administrator at the Centers for Medicare & Medicaid Services, where he worked on implementation of the Medicare Modernization Act and the Medicare Part D drug benefit, and helped advance the agency's coverage policies related to new medical technology. ^[10] Dr. Gottlieb had previously worked as a healthcare analyst at the investment bank Alex. Brown & Sons in Baltimore, and as a member of the editorial staff of the British Medical Journal and a section of the Journal of the American Medical Association.

References